One year after the pro-democracy Apple Daily newspaper was forced to close amid an investigation by national security police, its former journalists are struggling to come to terms with the loss of the paper, an often sensationalist, sometimes hard-hit…
Continue ReadingMONTREAL, June 23, 2022 (GLOBE NEWSWIRE) — Presagis, a global leader in 3D advanced modelling and simulation software, is releasing the 3D Environments Add-In application for Esri’s ArcGIS Pro. 3D Environments allows ArcGIS users to rapidly transform 3D Tiles Next data formats, such as One World Terrain, into ArcGIS Pro projects to create 3D scenes […]
Continue ReadingQatar Tourism DOHA, Qatar, June 23, 2022 (GLOBE NEWSWIRE) — With more than one million visitors set to visit Qatar for the FIFA World Cup Qatar 2022™, fans should be rest assured that incredible experiences, local culture, food and flavours are all available at fantastic value for money – or even for free. Chief Operating […]
Continue ReadingSinch Ranked Tier One by ROCCO Stockholm, Sweden – 23 June 2022 – Sinch AB (publ), a global leader in cloud communications and mobile customer engagement, today announced that it has been awarded the highest ‘Tier One’ ranking in recent reports from Roaming Consulting Company (ROCCO) for its Application-to-Person (A2P) SMS Monetization suite and A2P […]
Continue ReadingDetained State Counselor Aung San Suu Kyi began her trial on Thursday in a special court in Naypyidaw Prison. The National League for Democracy (NLD) leader was moved to the prison in Myanmar’s capital city and placed in solitary confinement on Wednesd…
Continue ReadingFestival founded by astrophysicist Dr. Garik Israelian and Dr. Brian May, astrophysicist and the legendary guitarist of Queen, will be held in Armenia and dedicated to the 50th anniversary of the first soft landing on Mars by “Mars 3” and the first orbiter “Mariner 9”. Dr Garik Israelian, astrophysicist and co-founder of STARMUS LONDON, June […]
Continue ReadingPhilogen Provides Corporate Update 211 out of 214 patients recruited in European Phase III trial investigating the neoadjuvant Nidlegy™ treatment of Stage IIIB/C melanoma, in line with expectations. Fibromun further demonstrates potent activity in recurrent glioblastoma with durable major responses. Pivotal clinical trials in soft–tissue sarcoma and glioblastoma are on track. OncoFAP shows potent activity […]
Continue Reading